



Table S1. Characteristics of sarcoidosis patients. Data is shown as absolute numbers and percentage.

Parameter	<i>n</i>	
Age ^a (years)	60	43.5 ± 12.1
Male sex	32/60	46.7%
Ever smoker	33/60	55.9%
Caucasian	49/60	81.7%
Löfgren syndrome	2/60	3.4%
Medication at time of biopsy	7/60	11.7%
Third-line therapy ^b	24/60	40.0%
COS group 2 years follow up	55/60	
Group 1-6	17	30.9%
Group 7-9	38	69.1%
COS group 5 years follow up	47/60	
Group 1-6	18	38.3%
Group 7-9	29	61.7%
Scadding stage at time biopsy	42/60	
Stage 0	1	2.4%
Stage I	13	31%
Stage II	16	38.1%
Stage III	7	16.7%
Stage IV	5	11.9%
Inflammatory biomarkers ^c	<i>Ref.range</i>	
ACE (U/L)	12-70	46.6 ± 34.9
sIL-2R (pg/mL)	<3000	5133.2 ± 3028.6
Extra pulmonary involvement	41/60	68.3%
Skin	21/60	35.0%
Eyes	4/60	6.7%
Liver	7/60	11.7%
Heart	9/60	15%
Spleen	2/60	3.3%
Bones	4/60	6.7%
Nerve system	11/60	18.3%
SFN	7/60	11.7%

^aAge at time of biopsy and is shown as mean ± SD. ^bThird-line therapy consisted of infliximab use at follow up. ^cbiomarkers at time of diagnosis and is shown as mean ± SD. COS: Clinical outcome status, SFN: Small fiber neuropathy, Scadding stages: 0 = Normal chest radiograph; I = Bilateral hilar lymphadenopathy (BHL); II = BHL with pulmonary infiltrates; III = pulmonary infiltrates without BHL; IV = fibrosis.